A recent poll by the Pistoia Alliance highlights the uneven impact of AI in life sciences, emphasizing that regulatory teams are reaping the most benefits, while wet lab applications remain largely undervalued.
The data, gathered at the Alliance's annual European conference in London, indicates that while nearly 30% of life sciences organizations have adopted enterprise-wide AI platforms, a significant 69% lack metrics to evaluate AI's effectiveness in reducing costs or timelines in drug R&D. Only 4% of respondents reported concrete advantages from AI in R&D leadership roles.
Notably, the survey reveals that more than half of the participants (54%) believe that regulatory submission teams are experiencing the most significant benefits from AI, in contrast to just 1% who see value in wet lab settings. The conference discussions spanned various themes, including the role of semantic data in enhancing interoperability and the importance of data standards in regulatory submissions.
Dr. Becky Upton, President of The Pistoia Alliance, pointed out that the gap between AI investment and its tangible benefits is a critical issue, stressing the need for improved data quality and accessibility. Dr. Christian Baber, Chief Portfolio Officer, echoed this sentiment, advocating for better collaboration between the pharmaceutical industry and regulators to advance AI applications in lab environments.
This survey underscores the necessity for a strategic approach to AI implementation in life sciences, particularly in ensuring that data management and regulatory practices evolve alongside technological advancements. As the industry progresses, addressing these gaps will be essential for maximizing AI's potential in drug development.